Related Experiment Video

Updated: Apr 6, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

36.1K

The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer

Isabel Heidegger1, Petra Massoner1, Natalie Sampson1

  • 1Division of Experimental Urology, Department of Urology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria.

Cancer Letters
|August 2, 2015
PubMed

Insights

Targeting the insulin-like growth factor (IGF) axis shows promise for prostate cancer (PCa) treatment, but clinical results are mixed. Further research is needed to overcome resistance and improve efficacy of novel therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Prostate cancer (PCa) is a leading cause of cancer death in males, with resistance to therapies limiting treatment efficacy.
  • The insulin-like growth factor (IGF) axis is frequently overexpressed in PCa, making it a significant therapeutic target.
  • Preclinical studies suggest targeting IGF axis receptors can yield anti-tumor effects in PCa.

Purpose of the Study:

  • To review preclinical and clinical studies investigating the IGF axis in prostate cancer.
  • To summarize the efficacy and limitations of IGF axis-targeting agents, including monoclonal antibodies and tyrosine kinase inhibitors.
  • To discuss the role of the IGF axis in biomarkers, such as IGF-binding proteins and genetic variants.

Main Methods:

  • Literature review of preclinical and clinical studies on the IGF axis in prostate cancer.
  • Analysis of data from studies using monoclonal antibodies and tyrosine kinase inhibitors targeting the IGF axis.
  • Summary of preliminary results from ongoing clinical trials.

Main Results:

  • Preclinical studies demonstrate significant anti-tumor effects of targeting the IGF axis in PCa.
  • Clinical studies evaluating IGF axis-targeting agents have not yet met expectations.
  • Ongoing studies are exploring novel treatment strategies and biomarker applications.

Conclusions:

  • The IGF axis remains a promising target for prostate cancer therapy, despite current clinical trial limitations.
  • Further research is essential to overcome drug resistance and optimize treatment strategies involving the IGF axis.
  • Biomarkers related to the IGF axis may play a crucial role in patient selection and treatment monitoring.
Keywords:
BiomarkerIGF targeting therapiesInsulin receptorInsulin-like growth factor receptor-1Prostate cancer

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.9K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K